7575-93-1

Usage

Uses

Used in Organic Synthesis:
Methyl-D3 p-toluenesulfonate is used as a reagent in organic synthesis for creating compounds with improved properties. Its deuterated nature allows for the synthesis of molecules with increased stability, which can be beneficial in various chemical applications.
Used in Pharmaceutical Research:
In pharmaceutical research, Methyl-D3 p-toluenesulfonate is used as a tool for metabolic tracking. The presence of deuterium atoms in its structure enables researchers to monitor the metabolism of compounds in biological systems, providing valuable insights into drug development and optimization.
Used in Chemical Analysis:
Methyl-D3 p-toluenesulfonate is employed as an internal standard in chemical analysis, particularly in mass spectrometry. The incorporation of deuterium atoms allows for accurate quantification and identification of target compounds, enhancing the reliability of analytical results.

Upstream product

• 1849-29-2 1,1,1-trideuteromethanol 
• 98-59-9 p-toluenesulfonyl chloride 
• 811-98-3 d⁽⁴⁾-methanol 
• 84989-67-3 methyl 9,9-bis(ethylthio)fluorene-1-carboxylate 

Downstream Products

• 139219-32-2 2-bromo-1,5,6,8-tetramethoxy-4-(methoxy-d₃)-3-(phenylethynyl)naphthalene 
• 104714-88-7 resorcinol O-mono-trideuteriomethyl ether 
• 170800-51-8 cis-4-tert-butyl-1-(d3-methoxy)cyclohexane 
• 1204219-82-8 4-bromo-1-chloro-2-(4-(methoxy-d3)benzyl)benzene 
• 1204221-76-0 (5-bromo-2-chlorophenyl)(3,5-difluoro-4-(methoxy-d3)phenyl)-methanone 
• 1204219-53-3 4-bromo-1-chloro-2-((4-(methoxy-d3)phenyl)methyl-d2)benzene 
• 1286216-69-0 benzyl 2-(methyl-d3)-3-oxobutanoate 
• 1204219-57-7 (2S,3R,4R,5S,6R)-2-(4-chloro-3-((4-(methoxy-d3)phenyl)-methyl-d2)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1204219-59-9 (2S,3R,4R,5S,6R)-2-(4-chloro-3-((4-(methoxy-d3)phenyl)-methyl-d2)phenyl)-2-d-6-(hydroxymethyl)tetrahydro-2Hpyran-3,4,5-triol 
• 1204219-88-4 (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(methoxy-d3)benzyl)-phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1407505-98-9 N-methyl-d₃ tert-butyl para-toluenesulfonylcarbamate 
• 1286254-54-3 1-phenyl-[4,4'-²H₂]-1,3-butadiene 
• 558-21-4 fluoromethane-d3 
• 97941-90-7 N,N-Bis-(D₃-methyl)-p-toluolsulfonamid 

Relevant academic research and scientific papers

Deuterated compound and application thereof in treatment of cancer

The present invention relates to a deuterated compound and application thereof in the treatment of cancer. Specifically, the present invention provides the compound of formula (I) and pharmaceuticallyacceptable salt or ester thereof, and a pharmaceutical composition thereof. The compound and the pharmaceutical composition are used for inhibiting or regulating the activity of tyrosine kinase and treating disease symptoms or symptoms including cancer mediated by tyrosine kinase.

Selective C-O Bond Reduction and Borylation of Aryl Ethers Catalyzed by a Rhodium-Aluminum Heterobimetallic Complex

We report the catalytic reduction of a C-O bond and the borylation by a rhodium complex bearing an X-Type PAlP pincer ligand. We have revealed the reaction mechanism based on the characterization of the reaction intermediate and deuterium-labeling experiments. Notably, this novel catalytic system shows steric-hindrance-dependent chemoselectivity that is distinct from conventional Ni-based catalysts and suggests a new strategy for selective C-O bond activation by heterobimetallic catalysis.

Deuterated substituted butenamide and preparation method and application thereof

The invention belongs to the field of medicines, and particularly relates to deuterated substituted butenamide and a preparation method and application thereof. The deuterated substituted butenamide is prepared from the intermediate compound shown V. Compared with the prior art, the deuterated substituted butenamide is used. The deuterated substituted butane acetamide - N - oxide has a good anti-cancer effect, and the application prospect of the medicine is increased for anti-cancer treatment drugs. , The deuterated substituted butanamide and the deuterated substituted butane acetamide - N - oxide are prepared by the process, the operation is simple, the purity is high, the three wastes are few, and the process is environment-friendly and friendly.

Regiodivergent DH or HD Addition to Alkenes: Deuterohydrogenation versus Hydrodeuterogenation

The regioselective and regiodivergent addition of H-D to a variety of 1,1-diarylalkenes was realized utilizing selectively deuterated dihydroaromatic compounds, which were generated by cobalt catalysis. The reaction was initiated by catalytic amounts of B

Construction of Biaryls from Aryl Sulfoxides and Anilines by Means of a Sigmatropic Rearrangement

An unprecedented S?N variant of the benzidine rearrangement for construction of biaryls has been developed. Aryl sulfoxides underwent dehydrogenative coupling with anilines by successive treatment with trifluoromethanesulfonic anhydride and trifluorometha

INDUSTRIAL PROCESS OF MONO-ALKYLATING A PIPERIDINE NITROGEN IN PIPERIDINE DERIVATIVES WITH DEUTERATED-ALKYL

The present invention relates to a method of mono-alkylating a piperidine nitrogen in a piperidine derivative with a deuterated lower-alkyl, which comprises protecting the piperidine nitrogen with an aralkyl protective group, lower-alkylating the piperidine nitrogen with a deuterated-lower-alkylating agent under neutral or basic condition, and then deprotecting the aralkyl protective group.

DEUTERATED 3-(4,5-SUBSTITUTED PYRIMIDINAMINE) PHENYL DERIVATIVES AND APPLICATIONS THEREOF

The present invention discloses a type of deuterated 3-(4,5-substituted aminopyrimidine)phenyl derivatives and use thereof. The derivatives are compounds of Formula (I) or pharmaceutically acceptable salts thereof. These compounds or salts thereof can be used for treatment or prevention of diseases or illnesses through certain mutant forms of epidermal growth factor receptors, inhibit the growth of various tumor cells effectively, and inhibit other proteases of EGFR and Her families, they can be used for preparing anti-tumor drugs.

THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF

Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with thyroid hormone receptor activity. The methods and compositions disclosed herein include the use of at least one thyroid hormone receptor agonist.

Preparation method and crystal form of deuterated diphenyl amino pyrimidine compound

The present invention discloses a preparation method and a crystal form of a compound shown in the formula (A) and also discloses a pharmaceutical composition comprising the crystal form of the compound shown in the formula (A) and a method for treating A

CRYSTALLINE FORM OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE

Disclosed is crystalline Form B of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl) amino)-N-(methyl-d3)pyridazine-3-carboxamide. Form B is the HCl salt of a neat crystalline form. Characterization data for Form B are disclosed.